I
nterleukin-33 (IL-33) is a member of the IL-1 superfamily and activates group 2 innate lymphoid cells (ILC2), mast cells, and their progenitors. Studies indicate that ILCs, which secrete copious amounts of IL-5 and IL-13 in response to IL-33, play critical roles in directing the development of type-2 immunity and allergic inflammation. In this issue of Cellular and Molecular Gastroenterology and Hepatology, Buzzelli et al 1 provide novel insights into the role that IL-33 exerts on the gastric immune response to infection with the pathogen Helicobacter pylori.
Chronic H. pylori-induced gastritis is mediated by a variety of constituents, including gastric epithelial cells, neutrophils, macrophages, and dendritic cells that lead to a T H 1-biased lymphocyte response. One microbial determinant that augments gastric cancer risk is the cag pathogenicity island, and cag þ strains significantly increase the risk for severe gastritis, atrophic gastritis, and cancer compared with strains lacking the cag island. 2 Another H. pylori factor, neutrophil-activating protein, promotes neutrophil recruitment, contributes to T H 1 polarization by stimulating both IL-12 and IL-23, and influences the production of T H 1 cells, resulting in increased production of interferon-g (IFN-g), tumor necrosis factor-a (TNF-a), and cytolytic activity of T helper (T H ) cells.
3 H. pylori also activates macrophages, resulting in the production of IL-1 and TNF-a, 4 in turn, promoting a T H 1-directed response. Dendritic cells (DCs) represent a critical bridge between the innate and adaptive immune responses. In response to H. pylori, DCs drive T H 1-effector responses, leading to production of TNF-a, IFN-g, and IL-2. 5 Consistent with a T H 1-type cytokine response, gastric lymphocyte populations from H. pylori-infected patients harbor IFN-gproducing T cells; after stimulation, these cells produce abundant levels of the T H 1 cytokines IFN-g and IL-2 and low levels of the T H 2 cytokines IL-4 and IL-5. 6 Collectively, the host immune response to H. pylori is predominantly a T H 1-type response, which leads to the development of a chronic inflammatory infiltrate that fails to eliminate this pathogen.
Buzzelli et al demonstrate that IL-33 expression is increased in response to acute H. pylori infection but is reciprocally suppressed during chronic H. pylori infection in mice and humans, which contributes to the dominant T H 1-polarized phenotype observed within infected gastric mucosa. To define the gastric response to IL-33 per se, mice were treated with recombinant IL-33. Chronic IL-33 administration led to increased gastric inflammation and the development of atrophy and metaplasia. Using flow cytometry to characterize immune cell populations in response to IL-33, the authors demonstrated no differences in the number of lymphocytes, but noted a significant expansion of myeloid-derived immunocytes, including macrophages, myeloid-derived suppressor cells, neutrophils, and DCs. IL-33 has been previously shown to activate ILC2, T H 2 immunocytes, and a T H 2 cytokine response, and chronic IL-33 administration results in increased expression of ILC2 markers and the T H 2 cytokine IL-4 in the stomach. Conversely, concomitant infection with H. pylori suppressed IL-33 production, which corresponded to decreased expression of ILC2 markers.
This study provides novel findings regarding the role of IL-33 in gastric immune responses, but more importantly, it has established a framework for future studies in this field. The authors demonstrate that IL-33 expression is increased with increasing bacterial abundance and diversity. This is noteworthy when viewed within the context of H. pylori infection, as infection with H. pylori leads to a decrease in the diversity of gastric microbial communities. 7 Thus, the diversity of the microbiome, in conjunction with a bacterial pathogen, may contribute to the complex regulation of IL-33.
The authors also demonstrate that expression of IL-33 in the stomach is partially regulated by TFF2. H. pylori upregulates TFF2 in gastric tissue in both humans and mice, and loss of TFF2 expression in vivo results in a significant increase in H. pylori-induced IFN-g production, gastric inflammation, atrophy, metaplasia, and dysplasia, 8 which may be related to TFF2-mediated regulation of IL-33. What could account for the ability of IL-33 alone to induce gastric atrophy and metaplasia, lesions that are also induced by H. pylori? Based on the dramatic and divergent expression pattern of IL-33 in response to H. pylori, follow-up studies should focus on additional host factors that regulate IL-33 expression in the stomach.
In terms of microbial determinants, the authors demonstrate that the H. pylori strain SS1 induces IL-33 during acute infection but suppresses IL-33 during chronic infection in mice. Because SS1 lacks a functional cag type IV secretion system, these data suggest that H. pylori strains that harbor a functional cag secretion system could differentially regulate IL-33 expression, which can be easily tested. Future studies that investigate mechanisms by which H. pylori temporally activates and suppresses IL-33 expression will be crucial in understanding immune responses to this gastric pathogen.
